ONCAlert | 2017 San Antonio Breast Cancer Symposium

The Clinical Activity of Rucaparib in Patients With Ovarian Cancer

Rebecca Kristeleit, BSc, PhD
Published Online: 3:02 PM, Tue October 11, 2016


Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.